Clinical Trial Update: Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating safety and immunogenicity of 2 or 3 doses of a MenACWY conjugate vaccine in healthy infants and the effect of a booster dose i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• MenACWY Conjugate Vaccine (Meningococcal conjugate vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2014-10-02